Vivimed Labs’ JV gets USFDA’s approval for Albendazole Tablets

12 Dec 2018 Evaluate

Vivimed Labs’ 50:50 Joint Venture (JV) strides vivimed Pte, Singapore has received approval for Albendazole Tablets USP 200mg from the United States Food & Drug Administration (USFDA). This is the second generic approval by USFDA for Albendazole Tablets.

Albendazole Tablets is a generic version of Albenza Tablets of Amneal pharmaceuticals, Inc. According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately $100 million.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Vivimed Labs Share Price

5.75 0.00 (0.00%)
31-Jul-2023 18:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×